Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer

Table 1

Clinical characteristics in prostate cancer (PCa) and benign prostate hyperplasia (BPH).

Parameter	PCa	BPH	value
Age (yrs)	70.5 (64–73)	67.4 (62.5–68.5)	0.51^a
BMI (kg/m^2)	26.4 (23.7–28.0)	26.4 (25.2–29.1)	0.20^a
T-Chol (mg/dL)	189.0 (170.0–220.0)	190.5 (161.5–199.5)	0.16^a
HDL (mg/dL)	39.5 (31.0–55.0)	40.0 (29.5–55.0)	0.78^a
TG (mg/dL)	152.6 ± 54.2	143.0 ± 43.6	0.38^b
LDL (mg/dL)	121.1 ± 28.7	123.0 ± 34.2	0.69^b
Glucose (mg/dL)	121.1 (104.0–126.5)	122.0 (108.5–132.0)	0.92^a
Insulin (IU/dL)	8.0 (5.7–11.0)	9.8 (6.8–15.4)	0.06^a
HOMA-IR	2.3 (1.7–3.7)	2.8 (1.8–4.9)	0.12^a
Omentin (ng/mL)	478.8 (398.2–584.7)	408.3 (323.3–528.0)	0.03^b
Leptin (ng/mL)	15.7 (8.2–26.8)	11.2 (6.0–16.0)	0.02^b
VEGF (pg/mL)	179.3 (116.0–266.0)	123.3 (70.8–192.7)	<0.01^b
HGF (pg/mL)	359.5 (266.6–462.9)	294.9 (192.1–353.7)	0.04^b
PSA (ng/mL)	18.2 (7.7–30.8)	9 (5.5–17)	<0.01^a
Prostate volume in TRUS (cm^3)	31.1 (20.0–38.2)	39.1 (24.9–47.5)	0.02^a

Significant differences of examined parameters between groups have been bolded. Statistic tests: ^aMann–Whitney’s U test, ^bStudent’s t-test. PCa: prostate cancer; BPH: benign prostate hyperplasia; BMI: body mass index; T-Chol: total cholesterol; HDL: high-density lipoprotein; TG: triglycerides; LDL: low-density lipoprotein; HGF: hepatocyte growth factor; VEGF: vascular endothelial growth factor.